AZN: Q1 2018 Results
AstraZeneca PLC 18 May 2018 07:00 Q1 2018 Results Encouraging launches and the performance of newer medicines underpin reiterated guidance As expected, the Product Sales performance benefitted from strong launches and the continued growth of newer medicines and China, offset by the erosion of Crestor sales. Progress was made on overall cost discipline, while the level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results. Patients continued